ASH 2021 | FT516: A novel NK cell therapy targeting B-cell lymphoma
Krish Patel, MD, Swedish Cancer Institute, Seattle, WA, presents results from a Phase I trial (NCT04023071) of FT516, an off-the-shelf allogeneic natural killer (NK) cell therapy, in patients with relapsed/refractory B-cell lymphomas (BCL). FT516 expresses a modified CD16 receptor and a total of 24 heavily-pre-treated patients have been enrolled so far. Preliminary data suggests promising efficacy in patients with little or no cases of cytokine release syndrome or immune effector cell-associated neurotoxicity syndrome (ICANS) reported. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.
Transcript (edited for clarity)
So this is a Phase I study of a natural killer cell therapy. It’s an off-the-shelf allogeneic natural killer cell therapy with a modified CD16 receptor, which gives it a high affinity binding to antibodies. So we are looking at that therapy called FT516 in patients with relapsed and refractory B-cell lymphomas. And we’ll be presenting the data at our poster session this evening, and we’ve treated, to date, about 20 patients in the clinical trial...
So this is a Phase I study of a natural killer cell therapy. It’s an off-the-shelf allogeneic natural killer cell therapy with a modified CD16 receptor, which gives it a high affinity binding to antibodies. So we are looking at that therapy called FT516 in patients with relapsed and refractory B-cell lymphomas. And we’ll be presenting the data at our poster session this evening, and we’ve treated, to date, about 20 patients in the clinical trial. Most of these patients are heavily pretreated, including several that are post T-cell therapy. And we’re seeing very interesting activity with responses in many different patient types, as well as a very differentiated safety profile. So we have not, to date, seen any CRS or ICANS using a natural killer cell based therapy as a cell therapy.
Read more...
